Alcobra Ltd. to Present at Upcoming Investment Conferences Company Will Host Corporate Update Conference Call & Webcast on November 17

TEL AVIV, Israel, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced upcoming corporate presentations at the Stifel 2015 Healthcare Conference and the Jefferies Autumn 2015 Global Healthcare Conference. The company will host a conference call and webcast on November 17 to provide a corporate update and discuss third quarter 2015 financial results.

Conference Call & Webcast
Tuesday, November 17 @ 8:30am Eastern
Domestic: 855-469-0611
International: 484-756-4341
Passcode: 56489875
Webcast: http://www.alcobra-pharma.com/events.cfm
Replays available through December 1, 2015
Domestic: 855-859-2056
International: 404-537-3406
Passcode: 56489875
Stifel 2015 Healthcare Conference
Date: Tuesday, November 17
Time: 11:00am ET
Location: Lotte New York Palace, New York, NY
Presenter: Dr. Yaron Daniely, CEO
Webcast: www.veracast.com/webcasts/stifel/healthcare2015/91105605087.cfm
Jefferies Autumn 2015 Global Healthcare Conference
Date: Thursday, November 19
Time: 12:40pm GMT (7:40 am ET)
Location: The Mayfair Hotel, London, UK
Presenter: Dr. Yaron Daniely, CEO
Webcast: http://wsw.com/webcast/jeff92/adhd/index.aspx

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 312-961-2502 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.